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N-acylhydrazone inhibitors of 
influenza virus PA endonuclease 
with versatile metal binding modes
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Gyanendra Kumar4, Stephen W. White4, Annelies Stevaert5 & Lieve Naesens5
Influenza virus PA endonuclease has recently emerged as an attractive target for the development of 
novel antiviral therapeutics. This is an enzyme with divalent metal ion(s) (Mg2+ or Mn2+) in its catalytic 
site: chelation of these metal cofactors is an attractive strategy to inhibit enzymatic activity. Here we 
report the activity of a series of N-acylhydrazones in an enzymatic assay with PA-Nter endonuclease, 
as well as in cell-based influenza vRNP reconstitution and virus yield assays. Several N-acylhydrazones 
were found to have promising anti-influenza activity in the low micromolar concentration range and 
good selectivity. Computational docking studies are carried on to investigate the key features that 
determine inhibition of the endonuclease enzyme by N-acylhydrazones. Moreover, we here describe the 
crystal structure of PA-Nter in complex with one of the most active inhibitors, revealing its interactions 
within the protein’s active site.
Influenza virus is an enveloped virus with a segmented negative-oriented single-stranded RNA genome, belong-
ing to the Orthomyxoviridae1. Seasonal influenza A and B viruses affect each year approximately 5–10% of the 
adult and 20–30% of the paediatric population2, and there is a permanent risk of sudden influenza pandem-
ics, such as the notorious ‘Spanish flu’ in 19183 and the swine-origin H1N1 pandemic in 20094. Two classes of 
anti-influenza virus drugs are available, acting on the viral M2 ion-channel (amantadine and rimantadine) or on 
the viral neuraminidase (zanamivir and oseltamivir). The M2 inhibitors have limited clinical utility due to their 
central nervous system side effects5 and widespread resistance, as in the case of the 2009 pandemic H1N1 virus6–8; 
resistance is also a growing concern for oseltamivir9. Therefore, there is an urgent need for new antiviral drugs 
with an entirely different mode of action10.
The influenza virus polymerase complex is composed of three subunits: PB1, PB2 and PA11,12. The PA subu-
nit performs the ‘cap-snatching’ endonuclease reaction, the PB2 subunit is responsible for initial binding of the 
capped RNAs, while the actual RNA synthesis is performed by the PB1 protein.
Given its crucial role in the viral life cycle, the influenza virus polymerase is widely recognized as a superior 
target for antiviral drug development13 and, in particular, inhibition of the PA endonuclease has deserved much 
attention in recent years14.
The endonuclease catalytic site resides in the N-terminal domain of PA (PA-Nter; residues 1~195)15–17. It com-
prises a histidine (His41) and a cluster of three strictly conserved acidic residues (Glu80, Asp108, Glu119), which 
coordinate (together with Ile120) one18, two15,19, or three20 manganese or magnesium ions. The two-metal-ion 
model is consistent with numerous biochemical findings21. Since the intracellular concentration of Mg2+ is at 
least 1000-fold higher than that of Mn2+, magnesium may be more biologically relevant22,23. A controversy about 
number and type of metal ions exists also for the active site of HIV-1 integrase14. HIV-1 integrase inhibitors are 
a paradigm for the innovative drug concept that is based on coordination with the metal cofactor(s) of viral 
enzymes14,24,25: similarly, several PA-binding agents with metal-chelating properties have been identified as 
influenza endonuclease inhibitors (Fig. 1), including 2,4-dioxobutanoic acid derivatives26,27, flutimide and its 
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derivatives28, 2-hydroxyphenyl amide derivatives29, as well as tetramic acids30, 5-hydroxypyrimidin-4-one deriv-
atives31, marchantins32 and green tea catechins, like epigallocatechin-3-gallate (EGCG, Fig. 1)33,34.
In recent years, we focused our research on chemical scaffolds that are able to chelate metal ions of PA-Nter, 
resulting in inhibition of influenza virus replication29,35. N-acylhydrazones represent an appealing class of chelat-
ing ligands with a broad spectrum of biological activities36,37, such as activity against HIV38–40, hepatitis A, vac-
cinia41,42 and influenza virus43. In the present work, we report the biological activity of a series of N-acylhydrazones 
(Fig. 2), as determined in an enzymatic assay with PA-Nter endonuclease as well as in cell-based influenza viral 
ribonucleoprotein (vRNP) reconstitution and virus yield assays. Several N-acylhydrazones were found to have 
promising anti-influenza activity with 50% effective concentration values (EC50) in the range of 3–20 μ M and 
good selectivity (Table 1 and Fig. 3). Computational docking studies of two candidate ligands in the PA-Nter 
active site gave information about the features that could determine inhibition of endonuclease activity. Moreover, 
we describe the X-ray crystal structure of PA-Nter in complex with one of the most active inhibitors.
Results and Discussion
Chemistry. N-acylhydrazones 1–27 (Fig. 2) were prepared in high yields by following literature methods42 
(Fig. 2A); they were characterized by spectroscopic tools, mass spectrometry and elemental analysis. Even if 
isomerism around the C = N bond is possible, 1–27 are present in the E form in solution, as evidenced by the 
chemical shift values of the HC = N and NH protons in the 1H-NMR spectrum44. Exceptions are represented by 
the alkyl-derivatives 3 and 4 (2:1 and 5:3 E:Z ratio, respectively).
If R’ (Fig. 2A) is a 2-hydroxy substituted phenyl ring, the corresponding acylhydrazones can coordinate one or, 
depending on denticity, two metal centers (modes A and B in Fig. 4). Starting from N’-(2,3-dihydroxybenzylidene)- 
semicarbazide (1) and its methoxy-analogue (2), we modified the acylhydrazonic substituent R” (3–8, 18, 19, 
Fig. 2A). In 18 and 19, also the gallic moiety can be involved in the chelation of the metal cofactors (mode C, 
Fig. 4). In order to investigate the role of hydroxyl substituents 9–11, 13–17, 20–23 and 27 were also synthesized. 
Compound 12 was synthesized in order to confirm the crucial influence of the gallic moiety. Finally, 26 was here 
considered, because it is an inhibitor of HIV RNase H38, another enzyme with two magnesium ions in its active 
site.
Since the inhibitory activity of the N-acylhydrazones could be related to chelation of the divalent metal cofac-
tor(s) in the influenza PA-Nter active site, we investigated the coordination properties of one model ligand (i.e. 19, 
H2L) towards Mg2+. Different reaction conditions were used (1:1 and 1:2 metal to ligand ratio, up to 4 equivalents 
of triethylamine), but in any case the same chemical species Mg(HL)2∙4H2O was recovered and conveniently 
characterized. The use of a coordinating solvent as d6-DMSO causes partial decoordination of the ligand, but 
the 1H-NMR spectrum in MeOD, instead, shows only the signals attributable to the complex. In the 13C-NMR 
spectrum, the signal of the C = O quaternary carbon is practically unaffected by complexation, suggesting that 
Figure 1. Chemical structures of some prototype inhibitors of influenza virus endonuclease. Inhibitor 
activity in enzymatic assays (IC50, μ M) as reported in: aref. 25, bref. 27, cref. 30, dref. 49.
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Figure 2. General synthesis for N-acylhydrazones 1–27 and hydrazides 28 and 29 (A). Chemical structures 
of compounds 1–27 (B). 
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the C = O group is weakly involved in the coordination to the metal ion. This is confirmed, in the IR spectrum, 
by the shift of about 20 cm−1 of the C = O absorption, while a shift of 30–50 cm−1 is expected when the carbon-
ylic oxygen is tightly bound to the metal ion42. ESI-mass spectra and elemental analysis confirmed the formula 
Mg(HL)2∙4H2O.
The interaction between the N-acylhydrazone ligands and the magnesium cation was investigated also by 
means of UV-visible spectroscopy (UV-visible titrations of 23 and 19 with increasing amount of Mg(CH3COO)2 
are shown in Figure S1). The spectrum of 19 includes a band at 313 nm assignable to n-π * transitions of the C = N 





Virus yield assay in influenza virus-
infected MDCK cellsb





IC50 EC99 EC90 CC50 EC50 CC50
(1) 24 NDf ND ND 107 > 200
(2) > 500 ND ND ND > 100 > 200
(3) > 500 ND ND > 200 5.9 48
(4) > 500 ND ND > 200 6.3 33
(5) 67 > 25 > 25 ≥ 146 2.6 10
(6) > 500 > 50 > 50 > 200 15 14
(7) 54 172 100 > 200 > 2.0 3.2 8.9
(8) > 500 > 12.5 > 12.5 > 200 1.9 15
(9) 34 16 5.3 > 200 > 38 5.5 > 200
(10) 68 14 8.5 111 > 13 0.40 132
(11) 45 30 12 > 200 > 17 5.6 > 200
(12) > 500 > 12.5 > 12.5 > 200 20 39
(13) 69 71 34 > 200 > 5.9 6.3 > 200
(14) > 500 63 37 > 200 > 5.4 2.3 > 200
(15) 8.9 18 7.5 ≥ 172 ≥ 23 14 > 200
(16) 454 67 28 > 200 > 7.1 5.2 > 200
(17) 482 21 8.1 > 200 > 25 7.1 > 200
(18) 83 6.2 2.2 > 200 > 91 3.3 > 200
(19) > 500 53 26 > 200 > 7.7 5.7 > 200
(20) 18 35 11 > 200 > 18 2.2 > 200
(21) 13 8.3 3.6 > 200 > 56 2.5 > 200
(22) 75 7.4 3.4 > 200 > 59 0.42 > 200
(23) 8.7 11 3.5 > 200 > 57 3.1 > 200
(24) 131 58 26 > 200 > 7.7 25 > 200
(25) 40 132 70 > 200 > 2.9 4.1 > 200
(26) 30 36 13 > 200 > 15 5.5 > 200
(27) 36 ND ND ND 21 > 200
(28) 40 158 85 > 200 > 2.4 7.2 > 200
DPBAe 5.3 ND ND ND ND ND
Ribavirin ND 13 8.5 > 200 > 24 9.4 > 200
Table 1. Inhibitory activity of the N-acylhydrazones 1–27 and hydrazide 28 in the enzymatic assay with 
influenza virus PA-Nter endonuclease, or in cellular influenza virus assays. aRecombinant PA-Nter was 
incubated with the ssDNA plasmid substrate, a Mn2+-containing buffer and test compounds. Cleavage of the 
substrate was assessed after 2 hr incubation. The IC50 represents the compound concentration (in μ M) required 
to obtain 50% inhibition of cleavage, calculated by nonlinear least-squares regression analysis (using GraphPad 
Prism software) of the results from 2–4 independent experiments. bMDCK cells were infected with influenza 
A virus (strain A/PR/8/34) and incubated with the compounds during 24 h. The virus yield in the supernatant 
was assessed by real-time qPCR. The EC99 and EC90 values represent the compound concentrations (in μ M) 
producing a 2-log10 or 1-log10 reduction in virus titer, respectively, determined in 2–3 independent experiments. 
The cytotoxicity, assessed in uninfected MDCK cells, was expressed as the CC50 value (50% cytotoxic 
concentration, determined with the MTS cell viability assay, in μ M). cHEK293T cells were co-transfected 
with the four vRNP-reconstituting plasmids and the luciferase reporter plasmid in the presence of the test 
compounds. The EC50 represents the compound concentration (in μ M) producing 50% reduction in vRNP-
driven firefly reporter signal, estimated at 24 h after transfection. The EC50 value was derived from data from 2–4 
independent experiments, by nonlinear least-squares regression analysis (using GraphPad Prism software). The 
CC50 (in μ M), i.e. the 50% cytotoxic concentration, was determined in untransfected HEK293T cells by MTS 
cell viability assay. dSI, selectivity index, defined as the ratio between the CC50 and EC90. eDPBA, 2,4-dioxo-4-
phenylbutanoic acid. fND, not determined.
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and a new band appears with a maximum at 397 nm. The opposite trend is observed in the range 300–350 nm, 
where an isosbestic point is present close to 335 nm. When the same experiment was performed with 23, a 
Figure 3. Overview of the structure-activity relationship for compounds 1–27. 
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different behavior was observed. Increasing concentration of Mg2+, in fact, caused a diminution in the maximum 
absorption, an isosbestic point is visible at about 345 nm, but a new band at 400 nm does not appear. Ligands 19 
and 23 coordinate the Mg2+ ions in different ways: 19 chelates the metal ion by using the deprotonated salicyl 
oxygen and the iminic nitrogen, while for 23, the gallic moiety is supposed to be involved (Fig. 4A,B versus C), 
leading to different, less extensive, modifications of the UV spectrum. These results will be revisited during the 
discussion of the biological activity.
Inhibition of the PA-Nter enzyme. All the compounds were tested for their ability to inhibit the influenza 
endonuclease in an enzymatic plasmid-based assay with recombinant PA-Nter27, as well as in cell-based influenza 
methods (i.e. virus yield and vRNP reconstitution assays)45. The results are shown in Table 1 and summarized in 
Fig. 3 to visualize the structure-activity relationships; Figure S2 shows the dose-response curves for three repre-
sentative compounds (i.e. 10, 13 and 23) in either the PA-enzyme or vRNP reconstitution assay.
The moderate activity (IC50 = 24 μ M) of N’-2,3-dihydroxybenzylidene semicarbazide (1) was completely lost 
when the NH2 moiety was replaced by a hydrophobic heptyl chain (3), but it is less affected when a phenyl 
or a 2-hydroxyphenyl is present (5 and 7, IC50 = 84 and 54 μ M, respectively). When the hydroxyl in position 
3 on R1 (2,3-dihydroxybenzylidene) was replaced by a methoxy group (2-hydroxy-3-methoxybenzylidene), 
Figure 4. Scheme of possible binding modes of the studied N-acylhydrazones. 
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the activity disappeared (compounds 2, 4, 6 and 8). The activity is unaffected (IC50 values ranging from 
45 to 75 μ M) when going from two hydroxyls in R1 (7) to compounds with three hydroxyls (i.e. 9, 10 and 
11). Similarly, 11 (R1 = 3,4,5-trihydroxyphenyl, R2 = 2-hydroxyphenyl) had comparable activity as 27 
(R1 = 3,4,5-trihydroxyphenyl, R2 = NH2). Within the series carrying a 2-hydroxyphenyl R2 group, the activity 
of 11 is particularly intriguing. 11 does not have the possibility to chelate in a tridentate ONO fashion (mode A 
in Fig. 4), but it can coordinate two cations by means of its three OH groups in R1 (mode C, Fig. 4). Note that a 
similar chelating mode was observed in a crystal structure, solved by Cusack and coworkers46, of PA-Nter endo-
nuclease in complex with the inhibitor EGCG.
The PA-Nter inhibitory activity strongly depends on the number and position of hydroxyl substitu-
ents in R1 and R2: this is clearly highlighted by the data obtained with compounds 13–23, in which R2 is a 
3,4,5-trihydroxyphenyl (gallic) group, the most active scaffold in our series. The analogue carrying an unsub-
stituted aromatic ring as R1 (compound 13) had moderate activity (IC50 = 69 μ M). When one OH was added 
at position 2 of the R1 ring (14), the activity was lost. Adding a second OH substituent at position 5 resulted in 
strong activity (compound 15, IC50 = 9 μ M); medium activity for a 3-OH (18; IC50 = 83 μ M), and marginal activ-
ity when the second OH is at position 4 (17, IC50 ≥ 370 μ M). The addition of a 3-methoxy group (19) abolished all 
inhibitory activity. This cannot be related to variations in the chelating features displayed by the R1 moiety, since 
compounds 14–19 all have, in theory, the capacity to chelate one metal ion through the ortho-OH and iminic 
nitrogen (mode A in Fig. 4). Moreover, compound 18 can, in principle, chelate the two M2+ ions in the active site 
according to mode B (Fig. 4), yet it (IC50 = 83 μ M) has nine-fold lower activity than 15, that does not possess this 
two-metal chelating feature. Therefore, we hypothesized that the inhibitory activity of the series containing the 
gallic moiety is determined by: (i) the capacity of the moiety R2 to chelate two metal ions in the active site of the 
enzyme, according to mode C (Fig. 4); and (ii) the presence and position of one or more hydroxyl substituents 
in R1, which may possibly result in ligand-protein interactions (e.g. through hydrogen bonds). This assumption 
was supported by molecular docking calculations and X-ray analysis of inhibitor 23 in complex with PA-Nter 
(vide infra). At this point, change of the substituents in R1 represents the next logical step. Substitution of the 
5-hydroxyl in 15 by a methoxy group (16) causes a dramatic drop in activity (IC50 = 9 and 454 μ M for 15 and 16, 
respectively). When two or three OH groups are present in R1, their spatial disposition greatly affects the activity. 
In particular, all the compounds with a trihydroxylated phenyl group as R1 (i.e. 20, 21, 22 and 23) were able to 
inhibit PA-Nter quite potently. The lowest IC50 values were obtained for 21 and 23 (IC50 = 13 and 7 μ M, respec-
tively), which both have one of their three hydroxyl groups at position 5. The most active compound in this series 
was 23, which lacks the hydroxyl group at position 2 of R1, further confirming that this function is undesirable or 
even detrimental for inhibitory activity against PA-Nter, as already noticed above for 14.
Consistent with a crucial role of the R2 gallic moiety in metal chelation, the strong activity of 15 was com-
pletely lost in its 3,4,5-trimethoxy analogue 12. On the other hand, the R2 gallic containing compounds displayed 
moderate activity (IC50 values around 40 μ M) when R1 was absent (i.e. the 3,4,5-trihydroxybenzohydrazide 28, 
Fig. 2), or composed of an extended ring system (26) or a pyrrole ring (25). Still lower activity was seen with the 
pyridine analogue 24. Evidently, the 3,4,5-trihydroxybenzyl moiety at R2 is fundamental but not sufficient to 
ensure potent PA-Nter endonuclease inhibition, since the interactions of R1 with the amino acid side chains of 
the protein appear crucial in modulating activity.
Inhibition of vRNP activity or virus replication in cells. To determine the anti-influenza virus activity 
of compounds 1–28 in cell culture, we performed an influenza vRNP reconstitution assay in human embry-
onic kidney 293 T (HEK293T) cells, then subjected the active compounds (i.e. EC50 < 100 μ M) to a virus yield 
assay in influenza virus-infected Madin-Darby canine kidney (MDCK) cells (Table 1 and Fig. 3). For some 
N-acylhydrazone compounds, we observed quite potent and selective activity in the vRNP reconstitution assay. 
This indicates that they are able to inhibit viral RNA synthesis and suggests that they could be classified as orig-
inal PA inhibitors. Values for EC50 (vRNP) or EC90 (virus yield) in the range of 0.4–18 μ M were obtained for 
compounds 15 and 20–23, which all carry a 3,4,5-trihydroxyphenyl as R2, and possess either two (15) or three 
(20–23) hydroxyl substituents in the R1 moiety. As in the enzymatic PA-Nter assays, the compounds having 
R2 as a gallic moiety (Fig. 3: 21, 22 and 23) showed slightly higher activity than the compounds carrying a 
2-hydroxyl R2 group (9, 10 and 11); 10 and 22 have substantially the same EC50 in the vRNP reconstitution assay 
in HEK293T cells.
The hydrazide 28 displayed weak (virus yield) to moderate (vRNP reconstitution) activity, albeit less than the 
most active molecules in the 3,4,5-trihydroxyphenyl series (i.e. 18 and 21–23). Even if there are no data indicating 
that the compounds reported in the paper are subject to hydrolysis, the activity of 28 could raise the concern that 
for some N-acylhydrazones the antiviral activity in cell culture may be related to their intracellular hydrolysis. 
However, this is unlikely, since the antiviral potency showed large differences (i.e. EC50 values between 0.42 and 
29 μ M) for compounds with the same R2 but different R1 groups, meaning that R1 does play a role in modulating 
the antiviral effect.
Most compounds carrying as R1 a 2,3-dihydroxybenzylidene (i.e. 3, 5 and 7) or 2-hydroxy-3-methoxybenzylidene 
moiety (i.e. 4, 6 and 8) showed relatively high cytotoxicity in the vRNP assay, with CC50 values below 50 μ 
M and a selectivity index (ratio of CC50 to EC50) below 8. Two notable exceptions are 18 and 19 (containing a 
2,3-dihydroxybenzylidene or 2-hydroxy-3-methoxybenzylidene R1, respectively) which were not cytotoxic at 200 μ 
M and displayed favorable antiviral selectivity.
Some N-acylhydrazone compounds were devoid of activity in the enzymatic assay, yet showed good to mod-
erate efficacy in cell culture (e.g. 14 and 19, having EC50 values of 2.2 and 7.1 μ M, respectively). For most of 
the active compounds (i.e. 9, 11, 13, 15–21, 23, 24 and 26) a fair correlation was seen for the two cell-based 
assays, since the EC50 values obtained in the vRNP assay were maximum 5-fold different from the EC90 values 
www.nature.com/scientificreports/
8Scientific RepoRts | 6:31500 | DOI: 10.1038/srep31500
in the virus yield assay. On the other hand, this difference was 8-fold or more for 7, 10, 14, 22, 25 and 28. Some 
N-acylhydrazone compounds showed good to moderate efficacy in the vRNP assay (e.g. 14 and 19, having EC50 
values of 2.3 and 5.7 μ M, respectively), yet were devoid of activity in the enzymatic assay. This observation sug-
gests that they may inhibit the viral polymerase in an endonuclease-independent manner. To achieve a clear 
insight into the antiviral profile of the N-acylhydrazones, specific mechanistic experiments are currently ongoing 
in our laboratory, in which we are analyzing in full depth their effects on virus entry, polymerase-dependent RNA 
synthesis or the late stage (maturation and release) of the virus replication cycle.
Docking studies. In order to explore the possible binding mode of the synthesized compounds, docking 
simulations by GOLD program47 were performed by using the structural coordinates (PDB code 4AWM) for 
the PA-Nter endonuclease in complex with EGCG46. Considering that the position of the side-chains of some 
residues changes depending on which pocket the ligand is occupying, we superimposed some X-ray structures of 
complexes between PA-Nter endonuclease and known active ligands. It was observed that the side-chain of amino 
acid Tyr24 shows greater movement than the other residues and for this reason we considered it as a flexible res-
idue during the docking procedure.
First, test docking calculations, using EGCG, L-742,001 and 2-(4-(1H-tetrazol-5-yl)phenyl)-5-hydroxypyrimidin- 
4(3H)-one (Fig. 1), were carried out to compare experimental and predicted binding modes and validate docking 
procedure. Their best docking poses agreed well with the experimental binding modes (rmsd values of 0.8, 1.2 
and 0.7, respectively).
Next, docking of several N-acylhydrazones was performed and this generated a number of possible binding 
conformations, highlighting that the active site cavity of the PA endonuclease is quite spacious, as already demon-
strated by crystallographic studies19,46, and confirming the ability of this scaffold to chelate the two M2+ ions in 
different ways (Mode A-C in Fig. 4).
Figure 5 displays the first (panel A) and second (panel B) GOLD cluster docked solutions for compound 23. 
These two complex structures represent the largest clusters with similar fitness values (59.20 and 58.65, respec-
tively). In both cases, 23 appears able to coordinate the two M2+ ions in the active site through the three con-
tiguous OH groups (Fig. 5). In addition, 23 was predicted to form two hydrogen bonding interactions, i.e. with 
the catalytic Lys13448 on the one side and Glu26 on the other side. Furthermore, in these two different binding 
modes, 23 forms π –π interactions with the aromatic ring of Tyr24, in a fashion similar to that described for other 
endonuclease inhibitors, i.e. EGCG46 and L-742,00119.
The best docked conformation for compound 15 (Fig. 6, fitness value 68.56), which has an activity slightly 
lower than 23, reveals a different role for the gallic moiety. The ligand seems to form two hydrogen bonding 
interactions with Tyr130 as well as a cation–π interaction with Lys134. Tyr130 lies in a pocket that also contains 
Arg124, a residue that was proposed to have a crucial role in binding of the RNA substrate16,45,49. Compound 
15 appears further stabilized by hydrogen bonding interactions between two hydroxyl groups and Arg82 and 
Asp108. In this case, chelation of the two M2+ ions is carried out by involving the imine group (mode A in Fig. 4).
It is important to highlight that compounds 23 and 15, although in different ways, both are able to chelate the 
metal cofactors and to establish interactions with highly conserved aminoacids (Tyr24, Glu26, Arg124, Tyr130 
and Lys134) that are very important for both endonuclease activity and transcription in vitro30,46,50. The crucial 
role of such interactions is underlined by the differences in activity between 15 (IC50 = 9.0 μ M) and 19 (> 500 μ M): 
their coordinating features are similar, since both coordinate to the divalent metal ion through the phenolic oxy-
gen, the iminic nitrogen and the carbonylic oxygen (mode A in Fig. 4), but the biological activity could be related 
to their different ability to engage interactions with the protein environment.
Crystallographic Studies. Attempts were made to co-crystallize PA-Nter with 15, 20, 21 and 23 in one to 
four molar excess. While crystals appeared and diffracted well, upon data processing, no or very little electron 
density for the inhibitors was observed. Attempts to soak apo crystals in crystallization solution containing 5 mM 
inhibitor overnight also did not result in substantial electron density for the inhibitor. As a last resort, dry powder 
of the inhibitor was sprinkled over the crystallization drop containing apo crystals and left over night. This exper-
iment was successful for compound 23, the crystals diffracted to 2.15 Å and diffraction data were collected (PDB 
ID 5EGA). The refined structure shows unambiguous electron density for the inhibitor (Table S1 and Fig. 7). The 
complex structure confirms one of the two binding modes predicted by the docking simulations (Fig. 5, panel B). 
The galloyl moiety chelates the manganese ions, while the trihydroxyphenyl group stacks against the Tyr24 side 
chain. It is interesting to note that two of these hydroxyl groups are in position to form hydrogen bonds with the 
side chain of Glu26 and Lys34 (Fig. 7). These interactions suggest that other functional groups, e.g. halogens, 
could be used in place of the hydroxyl groups for better interactions with Glu26 and Lys34 side chains, and the 
inhibitory potency of these compounds could be further improved.
Conclusions
The development of new agents for the treatment of influenza infection that exert their action by inhibition of the 
endonuclease activity of influenza RNA-dependent RNA polymerase is a strategy that recently is gaining a lot of 
interest13,27,31,43,51,52. The results here presented add the N-acylhydrazone scaffold to the library of the chelating 
molecules with potent antiviral activity (EC90 < 5 μ M, virus yield assay in influenza virus-infected MDCK cells). 
The structure of the N-acylhydrazone 23 co-crystallized with PA-Nter is important not only because confirms 
that the polyhydroxypheyl group efficiently coordinates two metal ions in the active site of the enzyme46, but also 
because highlights the importance of the (flexible) inhibitor backbone in order to engage effective interactions 
with crucial aminoacids of the protein. Inhibition of the endonuclease activity of influenza RNA-dependent RNA 
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polymerase could represent another example, after carbonic anhydrase, histone deacetylase, and HIV-1 integrase, 
of metal binding as a successful strategy in drug design14.
Experimental Section
Materials and methods. Chemistry. All reagents of commercial quality were purchased from Sigma-
Aldrich and used without further purification. The purity of the compounds was determined by elemental anal-
ysis and verified to be ≥95% for all synthesized molecules. NMR spectra were recorded at 25 °C on a Bruker 
Avance 400 FT spectrophotometer. The attenuate total reflectance IR spectra were recorded by means of a Nicolet-
Nexus (Thermo Fisher) spectrophotometer by using a diamond crystal plate in the range of 4000–400 cm−1. 
Elemental analyses were performed by using a FlashEA 1112 series CHNS/O analyzer (Thermo Fisher) with 
gas-chromatographic separation. Electrospray mass spectral analyses (ESI-MS) were performed with an electros-
pray ionization (ESI) time-of-flight Micromass 4LCZ spectrometer. MS spectra were acquired in positive EI mode 
by means of a direct exposure probe mounting on the tip of a Re-filament with a DSQII Thermo Fisher apparatus, 
equipped with a single quadrupole analyzer. UV–Vis spectra were recorded on an Evolution 260 Bio Thermo 
spectrophotometer by using cells of 1 cm path length. UV-vis absorption spectra of 19 and 23 were registered 
using a ca. 10−5 M solution in methanol. Each metal/ligand system was studied by titrating a 2.8 ml sample of 
the ligand solution with a methanolic solution of Mg(CH3COO)2; 8–12 spectra of samples with M:L molar ratio 
ranging from 0 to 6 were measured.
Synthesis of the ligands (general procedure). All the N-acylhydrazones were prepared in a manner 
similar to reported procedures42. Briefly, to a solution of the aldehyde in absolute ethanol or toluene, an equimolar 
amount of the hydrazide dissolved in the same solvent was added. The mixture was refluxed for 6 hours, cooled 
Figure 5. First (A) and second (B) GOLD cluster docked solutions of compound 23 (orange and cyan, 
respectively) in complex with PA endonuclease. Key residues of the pocket are presented using PyMOL [http://
www.pymol.org] and LIGPLUS [Laskowski, R. A.; Swindells, M. B. Journal of chemical information and modeling 
2011, 51, 2778]. Hydrogen bonds are illustrated by dotted lines, while the divalent metal ions are shown as 
purple spheres. Schematic drawings of the interactions of the first (C) and second (D) GOLD cluster docked 
solutions generated using LIGPLUS. Dashed lines are hydrogen bonds and ‘eyelashes’ show residues involved in 
hydrophobic interactions.
www.nature.com/scientificreports/
1 0Scientific RepoRts | 6:31500 | DOI: 10.1038/srep31500
at room temperature and concentrated in vacuum. The resulting precipitate was filtered off, washed with cold 
ethanol and dried in vacuum.
3,4,5-trihydroxybenzohydrazide (28) and 3,4,5-trimethoxybenzohydrazide (29) were obtained by reaction of 
the corresponding methyl esters with hydrazine monohydrate53. Hydrazine was added to an ethanol suspension 
of the ester and stirred at room temperature until the solute completely dissolved. Reaction mixture was then 
refluxed overnight. On concentrating the solution, a precipitate was observed, which was filtered and washed 
with cold ethanol. Chemical characterization of 1–29 and of Mg(HL)2 4H2O is collected in the Supplementary 
Information.
Computational Studies. The crystal structure of PA-Nter endonuclease in complex with EGCG was 
retrieved from the RCSB Protein Data Bank (entry code 4AWM). The ligand and water molecules were discarded 
and the hydrogens were added to the protein by Discovery Studio 2.5. The charge on the metal ions was set as +2. 
EGCG, L-742,001, and 2-(4-(1H-tetrazol-5-yl)phenyl)-5-hydroxypyrimidin-4(3H)-one structures were extracted 
from their X-ray complexes (PDB IDs 4AWM, 4W9S and 4E5H respectively). The other ligand structures were 
constructed using Discovery Studio 2.5.5 (Accelrys, Discovery Studio) and energy minimized using the Smart 
Minimizer protocol (1000 steps) which combines the Steepest Descent and the Conjugate Gradient methods.
The minimized ligands were docked in their corresponding proteins by means of GOLD Suite 5.0.154. The 
region of interest used by the GOLD program was defined in order to contain the residues within 15 Å from 
the original position of the ligand in the X-ray structure. The side-chain of residue Tyr24 was allowed to rotate 
according to the internal rotamer libraries in GOLD Suite 5.0.1. GoldScore was chosen as fitness function. The 
standard default settings were used in all calculations and the ligands were submitted to 100 genetic algorithm 
runs. The “allow early termination” command was deactivated. Results differing by less than 0.75 Å in ligand-all 
atom rmsd, were clustered together. The best GOLD-calculated conformation was used both for analysis and 
representation.
Plasmid-based endonuclease assay. This enzymatic assay was performed according to a previously pub-
lished method27. One microgram of recombinant PA-Nter (residues 1–217 from the PA protein of influenza virus 
strain A/X-31) was incubated with 1 μ g (16.7 nM) of single-stranded circular DNA plasmid M13mp18 (Bayou 
Biolabs, Metairie, Louisiana) in the presence of the test compounds and at a final volume of 25 μ L. The assay 
buffer contained 50 mM Tris-HCl pH 8, 100 mM NaCl, 10 mM β -mercaptoethanol and 1 mM MnCl2. The reac-
tion was incubated at 37 °C for 2 h and then stopped by heat inactivation (80 °C, 20 min), followed by visualization 
of the endonucleolytic digestion of the plasmid by gel electrophoresis on a 1% agarose gel with ethidium bromide 
staining. The amount of remaining intact plasmid was quantified by ImageQuant TL software (GE Healthcare, 
Figure 6. (A) Binding mode of compound 15 (orange) in complex with PA endonuclease. Key residues of 
the pocket are presented using PyMOL [http://www.pymol.org] and LIGPLUS [Laskowski, R. A.; Swindells, 
M. B. Journal of chemical information and modeling 2011, 51, 2778]. Hydrogen bonds are illustrated by dotted 
lines while the divalent metal ions are shown as purple spheres. (B) Schematic drawing of the interactions 
of compound 15 generated using LIGPLUS. Dashed lines are hydrogen bonds and ‘eyelashes’ show residues 
involved in hydrophobic interactions.
www.nature.com/scientificreports/
1 1Scientific RepoRts | 6:31500 | DOI: 10.1038/srep31500
Diegem, Belgium). The percentage inhibition of PA endonuclease activity was plotted against the compound con-
centration on a semi-logarithmic plot, using GraphPad Prism software (GraphPad Software, La Jolla, CA). The 
50% inhibitory concentrations (IC50) were obtained by nonlinear least-squares regression analysis of the results 
from three independent experiments. 2,4-Dioxo-4-phenylbutanoic acid (DPBA; Interchim, Montluçon, France) 
was included as the reference compound.
Cells and media. MDCK cells (a kind gift from M. Matrosovich, Marburg, Germany) and HEK293T cells 
(purchased from Thermo Fisher Scientific, Waltham, MA) were cultivated in Dulbecco’s modified Eagle medium 
supplemented with 10% fetal calf serum, 1 mM sodium pyruvate, and 0.075% sodium bicarbonate. During virus 
experiments, the MDCK cells were maintained in MDCK infection medium, consisting of Ultra MDCK medium 
(Lonza, Basel, Switzerland) supplemented with 0.0225% sodium bicarbonate, 2 mM L-glutamine, and 2 μ g/ml 
tosyl phenylalanyl chloromethyl ketone-treated trypsin (Sigma-Aldrich, St. Louis, MO). The cells were incubated 
in a humidified atmosphere containing 5% CO2.
vRNP reconstitution assay. The procedure to determine the inhibitory effect of the compounds on influ-
enza virus vRNPs reconstituted in HEK293T cells, is described in full detail elsewhere45. Briefly, the four relevant 
plasmids (i.e. the expression plasmids for PB1, PB2, PA and NP) were combined with the fluc reporter plasmid, 
and co-transfected into HEK293T cells using Lipofectamin 2000 (Invitrogen, Life Technologies, Gent, Belgium). 
After incubation at 37 °C for 24 h in the presence of serial dilutions of the test compounds, the ONE-Glo lucif-
erase assay system (Promega, Madison, WI) was used to determine luciferase activity. EC50 was defined as the 
compound concentration causing 50% reduction in the vRNP-driven firefly luciferase signal, as compared to cells 
receiving medium instead of compound. These EC50 values were calculated by interpolation assuming a semi-log 
dose-response effect using GraphPad Prism software. In parallel, compound cytotoxic activity was determined in 
untransfected HEK293T cells which had been incubated with serial dilutions of the compounds for 24 h, using 
the 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) cell 
viability assay (CellTiter 96 AQueous One Solution Cell Proliferation Assay; Promega). These spectrophotometric 
data were used to calculate the 50% cytotoxic concentration (CC50), i.e. the concentration reducing cell viability 
by 50%, as compared to wells receiving medium instead of compound. Ribavirin (Virazole; ICN Pharmaceuticals, 
Costa Mesa, CA) was included as the reference compound.
Figure 7. Crystal structure of PANΔLoop in complex with compound 23. Active site residues are shown in 
sticks with green carbons, manganese atoms are shown as purple spheres and water molecules as red spheres. 
Compound 23 is shown in sticks with yellow carbons. Protein secondary structure is shown as ribbons in 
salmon color. 2Fo-Fc electron density map contoured at 1σ is shown as blue mesh. Hydrogen bonds and metal 
coordination are shown with dotted lines. The H-bond distances from the side chain carboxyl group of Glu26 to 
p-OH and m-OH of the trihydroxyphenyl group of the inhibitor are 2.7 Å and 3.0 Å, respectively. The H-bond 
distance from the side chain of Lys34 to p-OH of the trihydroxyphenyl group is 3.6 Å. The H-bond distance to 
the water molecule from m-OH of the galloyl moiety is 3.0 Å, which in turn is H-bonded to the side chain of 
Tyr130 with a distance of 2.7 Å. Crystal structure has been deposited in the RCSB Protein Data Bank with PDB 
ID: 5EGA.
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Virus yield assay. We previously published in full detail the virus yield assay to determine the anti-influenza 
virus activity in MDCK cell cultures55. Briefly, one day prior to infection, MDCK cells were seeded into 96-well 
plates at 25,000 cells per well. At day 0, serial dilutions of the test compounds were added, immediately followed 
by infection with influenza A/PR/8/34 virus. After 24 h incubation at 35 °C, the virus amount in the superna-
tants was estimated by determining the viral genome copy number in a one-step quantitative real-time reverse 
transcription polymerase chain reaction (qRT-PCR) assay (CellsDirect One-Step qRT-PCR kit; Invitrogen), with 
influenza virus M1-specific primers and probe. The compound concentration values causing a 2-log10 (EC99) 
and a 1-log10 (EC90) reduction in viral RNA (vRNA) copy number at 24 h p.i., as compared to the virus control 
receiving no compound, were calculated by interpolation from data of at least three experiments. In parallel, the 
CC50 values after 24 h incubation with compounds were determined in uninfected MDCK cells, using the spec-
trophotometric MTS cell viability assay described above, respectively. Ribavirin was included as the reference 
compound.
Crystallographic analysis. A PAN construct (PANΔLoop) with a loop (residues 51–72) deleted and replaced 
with GGS from A/California/04/2009 H1N1 strain was used for the crystallographic studies. The details of clon-
ing, over-expression and purification are described elsewhere19,56. Briefly, the gene was cloned into pET52b vector 
and transformed into BL21 (DE3) cells, and the protein was expressed in LB medium overnight at 18 °C after 
induction at an OD600 ~0.8 with 0.2 mM isopropyl-β -thiogalactopyranoside (IPTG). The protein was purified 
from cell lysates by HisTrap affinity chromatography and the 10xHis tag was removed by digestion with thrombin. 
The protein was further purified by gel filtration using a Superdex 75 size-exclusion chromatography column in 
20 mM Tris pH 8.0, 150 mM NaCl and 1 mM TCEP. The protein was concentrated to 10–12 mg/ml for crystal-
lization. Crystals were grown in 0.2 M MgCl2, 2 mM MnCl2, 0.1 M Tris pH 8.5, 30% (w/v) PEG 4000 using the 
hanging drop method. For determination of the protein-inhibitor complex structure, the powder of the inhibitor 
was sprinkled on a 2 μ l drop of a 1:1 ratio mixture of protein solution and well solution, on a cover slide hang-
ing over 500 μ l well solution, and left overnight. Next day, the crystals were cryo-protected using well solution 
supplemented with 25% ethylene glycol and flash frozen in liquid nitrogen. The data were collected at the 22-ID 
beam line maintained by Southeast Regional Collaborative Access Team (SERCAT) at the Advanced Photon 
Source, Argonne National Laboratory. The data were indexed, integrated and scaled using the HKL2000 suite of 
programs57. Phase determination, structure refinement and model building were completed using Phaser, Refmac 
and Coot (part of the CCP4 package)58. The apo structure of PANΔLoop (PDB ID: 5DES) was used as starting model 
for molecular replacement. The details of the data collection and refinement statistics are given in Table S1.
References
1. Lamb, R. A. & Krug, R. M. Orthomyxoviridae: the viruses and their replication. In Fields virology, 4th ed. (Eds Knipe, D. M., Howley, 
P. M., Griffin, D. E., Lamb, R. A., Martin, M. A., Roizman, B., Straus, S. E.) 1487–1531 (Lippincott Williams & Wilkins: Philadelphia, 
2001).
2. World Health Organization. Influenza (seasonal) - Fact sheet N°211. http://www.who.int/mediacentre/factsheets/fs211/en/ 
(accessed 19-1-2015).
3. Taubenberger, J. K. & Morens, D. M. 1918 Influenza: the mother of all pandemics. Emerg. Infect. Dis. 12, 15–22 (2006).
4. Garten, R. J. et al. Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans. 
Science, 325, 197–201 (2009).
5. Jefferson, T., Demicheli, V., Di Pietrantonj, C. & Rivetti, D. Amantadine and rimantadine for influenza A in adults. Cochrane 
Database. Syst. Rev. CD001169 (2006).
6. Deyde, V. M. et al. Surveillance of resistance to adamantanes among influenza A(H3N2) and A(H1N1) viruses isolated worldwide. 
J. Infect. Dis. 196, 249–257 (2007).
7. Moscona, A. Global transmission of oseltamivir-resistant influenza. N. Engl. J. Med. 360, 953–956 (2009).
8. Memoli, M. J. et al. Multidrug-resistant 2009 pandemic influenza A(H1N1) viruses maintain fitness and transmissibility in ferrets. 
J. Infect Dis. 203, 348− 357 (2011).
9. van der Vries, E., Schutten, M., Fraaij, P., Boucher, C. & Osterhaus, A. Influenza virus resistance to antiviral therapy. Adv. Pharmacol. 
67, 217–246 (2013).
10. Vanderlinden, E. & Naesens, L. Emerging antiviral strategies to interfere with influenza virus entry. Med. Res. Rev. 34, 301–339 
(2014).
11. Pflug, A., Guilligay, D., Reich, S. & Cusack, S. Structure of influenza A polymerase bound to the viral RNA promoter. Nature 516, 
355–360 (2014).
12. Boivin, S., Cusack, S., Ruigrok, R. W. & Hart, D. J. Influenza A virus polymerase: structural insights into replication and host 
adaptation mechanisms. J. Biol. Chem. 285, 28411–28417 (2010).
13. Stevaert, A. & Naesens, L. The influenza virus polymerase complex: an update on its structure, functions and significance for 
antiviral drug design. Med. Res. Rev. In press.
14. Rogolino, D., Carcelli, M., Sechi, M. & Neamati, N. Viral enzymes containing magnesium: metal binding as a successful strategy in 
drug design. Coord. Chem. Rev. 256, 3063–3086 (2012).
15. Dias, A. et al. The cap-snatching endonuclease of influenza virus polymerase resides in the PA subunit. Nature 458, 914–918 (2009).
16. Yuan, P. et al. Crystal structure of an avian influenza polymerase PA(N) reveals an endonuclease active site. Nature 458, 909–913 
(2009).
17. Tefsen, B. et al. The N-terminal domain of PA from bat-derived influenza-like virus H17N10 has endonuclease activity. J. Virol. 88, 
1935–1941 (2014).
18. Zhao, C. et al. Nucleoside monophosphate complex structures of the endonuclease domain from the influenza virus polymerase PA 
subunit reveal the substrate binding site inside the catalytic center. J. Virol. 83, 9024–9030 (2009).
19. DuBois, R. M. et al. Structural and biochemical basis for development of influenza virus inhibitors targeting the PA endonuclease. 
PLoS Pathog. 8, e1002830 (2012).
20. Bauman, J. D. et al. Crystallographic fragment screening and structure-based optimization yields a new class of influenza 
endonuclease inhibitors. ACS Chem. Biol. 8, 2501–2508 (2013).
21. Doan, L., Handa, B., Roberts, N. A. & Klumpp, K. Metal ion catalysis of RNA cleavage by the influenza virus endonuclease. 
Biochemistry 38, 5612–5619 (1999).
22. Maret, W. Metalloproteomics, metalloproteomes, and the annotation of metalloproteins. Metallomics 2, 117–125 (2010).
23. Jahnen-Dechent, W. & Ketteler, M. Magnesium basics. Clin. Kidney J. 5, i3–i14 (2012).
www.nature.com/scientificreports/
13Scientific RepoRts | 6:31500 | DOI: 10.1038/srep31500
24. Summa, V. et al. Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-
AIDS infection. J. Med. Chem. 51, 5843–5855 (2008).
25. Johns, B. A. et al. Carbamoyl pyridone HIV-1 integrase inhibitors 3. A diastereomeric approach to chiral nonracemic tricyclic ring 
systems and the discovery of dolutegravir (S/GSK1349572) and (S/GSK1265744). J Med. Chem. 56, 5901–5916 (2013).
26. Hastings, J. C., Selnick, H., Wolanski, B. & Tomassini, J. E. Anti-influenza virus activities of 4-substituted 2,4-dioxobutanoic acid 
inhibitors. Antimicrob. Agents Chemother. 40, 1304–1307 (1996).
27. Stevaert, A. et al. An integrated biological approach to guide the development of metal-chelating inhibitors of influenza virus PA 
endonuclease. Mol. Pharmacol. 87, 323–337 (2015).
28. Tomassini, J. E. et al. A novel antiviral agent which inhibits the endonuclease of influenza viruses. Antimicrob. Agents Chemother. 40, 
1189–1193 (1996).
29. Carcelli, M. et al. Metal-chelating 2-hydroxyphenyl amide pharmacophore for inhibition of influenza virus endonuclease. Mol. 
Pharmaceutics 11, 304–316 (2014).
30. Parkes, K. E. et al. Use of a pharmacophore model to discover a new class of influenza endonuclease inhibitors. J. Med. Chem. 46, 
1153–1164 (2003).
31. Sagong, H. Y. et al. Phenyl substituted 4-hydroxypyridazin-3(2H)-ones and 5-hydroxypyrimidin-4(3H)-ones: inhibitors of influenza 
A endonuclease. J. Med. Chem. 57, 8086–8098 (2014).
32. Iwai, Y. et al. Anti-influenza activity of marchantins, macrocyclic bisbibenzyls contained in liverworts. PLoS One 6, e19825 (2011).
33. Kuzuhara, T., Iwai, Y., Takahashi, H., Hatakeyama, D. & Echigo, N. Green tea catechins inhibit the endonuclease activity of influenza 
A virus RNA polymerase. PLoS Curr. 1, RRN1052 (2009).
34. Song, J. M., Lee, K. H. & Seong, B. L. Antiviral effect of catechins in green tea on influenza virus. Antiviral Res. 68, 66− 74 (2005).
35. Rogolino, D. et al. Investigation of the salicylaldehyde thiosemicarbazone scaffold for inhibition of influenza virus PA endonuclease. 
J. Biol. Inorg. Chem. 20, 1109–1121 (2015).
36. Rollas, S. & Küçükgüzel, S. G. Biological activities of hydrazone derivatives. Molecules 12, 1910–1939 (2007).
37. Verma, G. et al. A review exploring biological activities of hydrazones. J. Pharm. Bioallied Sci. 6, 69–80 (2014).
38. Gong, Q. et al. Interaction of HIV-1 reverse transcriptase ribonuclease H with an acylhydrazone inhibitor. Chem. Biol. Drug Des. 77, 
39–47 (2011).
39. Sanchez, T. W. et al. Discovery of novel inhibitors of LEDGF/p75-IN protein–protein interactions. Bioorg. Med. Chem. 21, 957–963 
(2013).
40. Herschhorn, A. et al. A broad HIV-1 inhibitor blocks envelope glycoprotein transitions critical for entry. Nat. Chem. Biol. 10, 
845–852 (2014).
41. Abdel-Aal, M. T., El-Sayed, W. A. & El-Ashry, El-S. H. Synthesis and antiviral evaluation of some sugar arylglycinoylhydrazones and 
their oxadiazoline derivatives. Arch. Pharm. (Weinheim) 339, 656–663 (2006).
42. Rogolino, D. et al. A versatile salicyl hydrazonic ligand and its metal complexes as antiviral agents. J. Inorg. Biochem. 150, 9–17 
(2015).
43. Chen, E. et al. Computation-guided discovery of influenza endonuclease inhibitors. ACS Med. Chem. Lett. 5, 61–64 (2014).
44. Palla, G., Predieri, G., Domiano, P., Vignali, C. & Turner, W. Conformational behaviour and E/Z isomerization of N-acyl and 
N-aroylhydrazones. Tetrahedron 42, 3649–3654 (1986).
45. Stevaert, A. et al. Mutational analysis of the binding pockets of the diketo acid inhibitor L-742,001 in the influenza virus PA 
endonuclease. J. Virol. 87, 10524–10538 (2013).
46. Kowalinski, E. et al. Structural analysis of specific metal chelating inhibitor binding to the endonuclease domain of influenza pH1N1 
(2009) polymerase. PLoS Pathog. 8, e1002831 (2012).
47. Jones, G., Willett, P., Glen, R. C., Leach, A. R. & Taylor, R. Development and validation of a genetic algorithm for flexible docking. 
Journal of Molecular Biology 267, 727–748 (1997).
48. Crépin, T. et al. Mutational and metal binding analysis of the endonuclease domain of the influenza virus polymerase PA subunit. J. 
Virol. 84, 9096–9104 (2010).
49. Xiao, S. et al. Magnesium-dependent RNA binding to the PA endonuclease domain of the avian influenza polymerase. J. Phys. Chem. 
B 118, 873–889 (2014).
50. Hara, K., Schmidt, F. I., Crow, M. & Brownlee, G. G. Amino Acid Residues in the N-Terminal Region of the PA Subunit of Influenza 
A Virus RNA Polymerase Play a Critical Role in Protein Stability, Endonuclease Activity, Cap Binding, and Virion RNA Promoter 
Binding J. Virol. 80(16), 7789–7798 (2006).
51. Yuan, S. et al. A novel small-molecule inhibitor of influenza A virus acts by suppressing PA endonuclease activity of the viral 
polymerase. Sci. Rep. 6, 22880, doi: 10.1038/srep22880 (2016).
52. Pala, N. et al. Virtual Screening and Biological Validation of Novel Influenza Virus PA Endonuclease Inhibitors. ACS Med. Chem. 
Lett. 6(8), 866–871 (2015).
53. Gwaram, N. S. et al. Synthesis, characterization, X-ray crystallography, acetyl cholinesterase inhibition and antioxidant activities of 
some novel ketone derivatives of gallic hydrazide-derived Schiff bases. Molecules 17, 2408–2427 (2012).
54. Jones, G., Willett, P., Glen, R. C., Leach, A. R. & Taylor, R. Development and validation of a genetic algorithm for flexible docking. J. 
Mol. Bio. 267, 727–748 (1997).
55. Vanderlinden, E. et al. Novel inhibitors of influenza virus fusion: structure-activity relationship and interaction with the viral 
hemagglutinin. J. Virol. 84, 4277–4288 (2010).
56. Song, M. S. et al. Identification and characterization of influenza variants resistant to a viral endonuclease inhibitor. PNAS, 113, 
3669–3674 (2016).
57. Otwinowski, Z. & Minor, W. Processing of X-ray diffraction data collected in oscillation mode. In Methods in Enzymology, Volume 
276: Macromolecular Crystallography, part A (Eds Carter, C. W. Jr., Sweet, R. M.) 307–326 (Academic Press, New York, 1997).
58. Winn, M. D. et al. Overview of the CCP4 suite and current developments. Acta Crystallogr. D Biol Crystallogr. 67, 235–42 (2011).
Acknowledgements
The authors wish to thank W. van Dam and Ria Van Berwaer for fine technical assistance, and Meehyein Kim 
(Korea Research Institute of Chemical Technology, Daejeon, South Korea) for the generous donation of the vRNP 
reconstitution plasmids. “Centro Interdipartimentale Misure Giuseppe Casnati” of the University of Parma is 
thanked for facilities. Diffraction data were collected at Southeast Regional Collaborative Access Team (SERCAT) 
beam line 22-ID at the Advanced Photon Source (APS), Argonne National Laboratory. Supporting SERCAT 
institutions may be found at  www.ser-cat.org/members.html. Use of the APS is supported by the US Department 
of Energy under Contract W‐31‐109‐Eng‐38. Work in the S.W.W. laboratory is supported by NIH Cancer Center 
core Grant CA21765 and the American Lebanese Syrian Associated Charities (ALSAC).
www.nature.com/scientificreports/
1 4Scientific RepoRts | 6:31500 | DOI: 10.1038/srep31500
Author Contributions
The manuscript was written through contributions of all authors. All authors have given approval to the final 
version of the manuscript. M.C., D.R., A.G. and M.S. drug design and chemical synthesis; L.D.L. docking studies; 
G.K. and S.W.W. crystallographic studies; A.S. and L.N. biological studies.
Additional Information
Supplementary information accompanies this paper at http://www.nature.com/srep
Competing financial interests: The authors declare no competing financial interests.
How to cite this article: Carcelli, M. et al. N-acylhydrazone inhibitors of influenza virus PA endonuclease with 
versatile metal binding modes. Sci. Rep. 6, 31500; doi: 10.1038/srep31500 (2016).
This work is licensed under a Creative Commons Attribution 4.0 International License. The images 
or other third party material in this article are included in the article’s Creative Commons license, 
unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, 
users will need to obtain permission from the license holder to reproduce the material. To view a copy of this 
license, visit http://creativecommons.org/licenses/by/4.0/
 
© The Author(s) 2016
